Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2025-03-12 00:00:00 ET · period of report 2025-03-10 · accession 0000950170-25-037880 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-03-12 | 2025-03-10 | TRVI | Simon Farrell | Chief Commercial Off | S - Sale+OE | $6.75 | -81.3K | 81.2K | -50% | -$549.1K |
| DMT | 2025-03-12 | 2025-03-10 | TRVI | Simon Farrell | Chief Commercial Off | M - OptEx | $2.86 | +112.6K | 63.1K | New | +$321.6K |
| DMT | 2025-03-12 | 2025-03-10 | TRVI | Simon Farrell | Chief Commercial Off | M - OptEx | $0.00 | -112.6K | 18.8K | -86% | $0 |
| DT | 2025-03-12 | 2025-03-10 | TRVI | Simon Farrell | Chief Commercial Off | A - Grant | $0.00 | +38.4K | 38.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-10 | S | D | 4,350 | $7.15 | 76,900 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 2 | Common | Common Stock | 2025-03-10 | M | A | 31,250 | $0.51 | 158,213 | D | — | — | |
| 3 | Common | Common Stock | 2025-03-10 | M | A | 63,813 | $3.91 | 126,963 | D | — | — | |
| 4 | Common | Common Stock | 2025-03-10 | M | A | 17,500 | $3.21 | 63,150 | D | — | — | |
| 5 | Common | Common Stock | 2025-03-10 | S | D | 76,963 | $6.73 | 81,250 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 6 | Derivative | Stock Option (right to buy) | 2025-03-10 | M | D | 63,813 | $0.00 | 11,187 | D | $3.91 · — to 2030-09-22 | 63,813 Common Stock | (F7) This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024. |
| 7 | Derivative | Performance Stock Option (right to buy) | 2025-03-10 | M | D | 17,500 | $0.00 | 0 | D | $3.21 · — to 2031-02-16 | 17,500 Common Stock | (F6) Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. |
| 8 | Derivative | Performance Stock Option (right to buy) | 2025-03-10 | A | A | 38,400 | $0.00 | 38,400 | D | $2.38 · 2025-03-10 to 2034-02-14 | 38,400 Common Stock | (F5) Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied. |
| 9 | Derivative | Stock Option (right to buy) | 2025-03-10 | M | D | 31,250 | $0.00 | 18,750 | D | $0.51 · — to 2032-02-10 | 31,250 Common Stock | (F8) This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |